On October 9, Everest Medicines (01952) announced the appointment of Dr. Lakshmi Srinivasan as Senior Vice President and Head of Translational Medicine, and Dr. Brandon Coder as Vice President of Translational Science and Early Research.

These appointments will further strengthen the company's global R&D capabilities and international collaboration layout for its mRNA technology platform.

In the future, the company will continue to bring together top international talent, integrate R&D resources, and accelerate the implementation of its global innovation strategy.

Both newly appointed executives possess deep industry experience and professional backgrounds, having previously been responsible for oncology vaccine research and development at globally leading biopharmaceutical companies such as Moderna, with complete hands-on experience spanning from early discovery to clinical translation and clinical development.

Under the leadership of Everest Medicines' management, the two senior scientists will focus on advancing the clinical development of the mRNA technology platform in the United States and related business layout, in line with the company's global mRNA R&D strategy, while working closely with the China R&D team to further empower the evolution of the mRNA technology platform.

Wu Yifang, Chairman of the Board of Everest Medicines, stated that he is very pleased to welcome Dr. Srinivasan and Dr. Coder to the company.

He noted that the two senior scientists possess profound experience in oncology vaccine research and development, translational medicine, and clinical development, which will further strengthen the company's global mRNA R&D capabilities and help advance the global clinical development of its proprietary mRNA technology platform and related product pipeline.

These appointments reflect Everest Medicines' commitment to continuously bringing together top global talent and advancing its global mRNA strategy.

As one of the few biopharmaceutical companies worldwide with a full-process, independently controllable mRNA technology platform, Everest Medicines has built a complete industrial chain platform covering antigen design, mRNA sequence optimization, lipid nanoparticle (LNP) targeted delivery technology, and industrial-scale production, possessing end-to-end capabilities across the mRNA platform value chain and having successfully achieved clinical validation.